Skip to main content

Reviva Pharmaceuticals Holdings, Inc 8-K, filed Nov 13, 2026

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

8-K 2026-11-13 For: 2026-11-12
View Original
Added on November 13, 2026

About this 8-K

Reviva Pharmaceuticals Holdings, Inc filed this 8-K on November 13, 2026, reporting on events of November 12, 2026.

Reviva reported a net loss of approximately $2.3 million, or $0.17 per share, for the three months ended September 30, 2026. FDA feedback on brilaroxazine is expected Q4 2026, and RECOVER-2 enrollment is targeted for 1H 2027, subject to additional financing. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits